

Appln. No. 10/521,193
Amdt. dated October 2, 2007
Reply to Office action of May 2, 2007

Amendments to the Abstract:

Please replace the previous abstract with the following sheet, which is a replacement abstract:

Appln. No. 10/521,193

Amdt. dated October 2, 2007

Reply to Office action of May 2, 2007

ABSTRACT

Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably administered orally with a pharmaceutically acceptable carrier.